Last $17.16 USD
Change Today +0.22 / 1.30%
Volume 61.8K
AXDX On Other Exchanges
As of 12:01 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

accelerate diagnostics inc (AXDX) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/27/14 - $31.86
52 Week Low
09/23/13 - $9.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

accelerate diagnostics inc (AXDX) Related Businessweek News

No Related Businessweek News Found

accelerate diagnostics inc (AXDX) Details

Accelerate Diagnostics, Inc. focuses on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel system, a rapid diagnostic platform for rapid diagnosis in life-threatening infectious pathogens. It also develops and licenses OptiChem surface coatings for use in microarraying components. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is based in Tucson, Arizona.

47 Employees
Last Reported Date: 03/7/14
Founded in 1982

accelerate diagnostics inc (AXDX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $300.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $170.0K
Chief Commercial Officer
Total Annual Compensation: $115.1K
Compensation as of Fiscal Year 2013.

accelerate diagnostics inc (AXDX) Key Developments

Accelerate Diagnostics, Inc., Annual General Meeting, May 29, 2014

Accelerate Diagnostics, Inc., Annual General Meeting, May 29, 2014., at 08:00 Mountain Standard Time. Location: Herbert K. Abrams Public Health Center, 1st Floor Conference Room. Agenda: To elect the following six persons to serve as directors of the company until the next Annual Meeting of Shareholders and thereafter until their successors shall have been elected and qualified: Lawrence Mehren, Mark C. Miller, John Patience, Jack Schuler, Matthew W. Strobeck, Ph.D. and Frank J.M. ten Brink; to approve an amendment to the company's 2012 Omnibus Equity Incentive Plan increasing the number of shares of the company's common stock reserved and available for grant there under by 4,000,000 shares; to ratify the selection of Ernst & Young LLP as the independent public accountants of the company for the year ending December 31, 2014; and to transact such other business as may properly come before the meeting or any continuation, postponement or adjournment thereof.

Accelerate Diagnostics Approves the Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2013

The 2013 Annual Meeting of Stockholders of Accelerate Diagnostics, Inc. was held on December 6, 2013 has approved the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2013.

Accelerate Diagnostics Mulls Acquisitions

Accelerate Diagnostics, Inc. (NasdaqCM:AXDX) has made an offering of $150 million. The proceeds of the offering will be used for general corporate purposes, which may include working capital, the repayment of debt obligations, other capital expenditures, research and development expenditures and/or acquisitions of new technologies or businesses.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AXDX:US $17.16 USD +0.22

AXDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AXDX.
View Industry Companies

Industry Analysis


Industry Average

Valuation AXDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14,084.9x
Price/Book 9.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12,927.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACCELERATE DIAGNOSTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at